Bentley University is a private co-educational university in Waltham, Massachusetts, 9 miles west of Boston, focused on business. Founded in 1917 as a school of accounting and finance in Boston's Back Bay neighborhood, Bentley moved to Waltham in 1968. Bentley awards bachelor of science degrees in 11 business fields and bachelor of arts degrees in 6 arts and science disciplines. The graduate school emphasizes the impact of technology on business practice, and offers PhD programs in Business and Accountancy, the Bentley MBA with 16 areas of concentration, an integrated MS+MBA, 7 Master of Science degrees, and custom executive education programs.Bentley's athletic teams compete in Division II of the NCAA and is known collectively as the Bentley Falcons. They compete in the Northeast-10 Conference. Wikipedia.
News Article | May 10, 2017
Most of the new drugs approved by the FDA since 2010 arose from basic scientific research that was initiated in the 1970s or 1980s, a new study from Bentley University has found. The analysis shows that development of new targeted and biological therapeutics rest on the maturation of basic science over decades. The research, published today in the journal PLOS One, appears as scientists are increasingly concerned about federal support for basic biomedical research. The PLOS One article, titled "Timelines of translational science: From technology initiation to FDA approval," uses an analytical model for the growth of basic research to examine the relationship between the progress of research and approval of new drugs based on this work. The study from Bentley's Center for Integration of Science and Industry examined all of the drugs approved by the FDA from 2010-2014. The analysis shows that basic biomedical research on drug targets follows predictable patterns of growth and maturation, and that the ability to successfully translate this science into new therapeutics depends on first achieving a certain level of maturation. "While we celebrate the 'a ha' moment of scientific discovery and invention, such moments are only the point of initiation for the basic research required to develop new drugs," said Dr. Laura McNamee, the lead author of the paper and a research associate in Bentley's Center for Integration of Science and Industry. "Our analysis shows that very few targeted or biological therapeutics emerge from this basic research until it becomes established." The paper published showed that the efficiency of drug development improved significantly when the enabling science passed an established point defined by the analytical model. No targeted or biological products were approved before this point, and clinical development of approved products was three years shorter for products that entered clinical trial trials after this point. "Translational medicine remains a largely empirical process, and we are only beginning to apply the theories and analytical tools of systems engineering and technology management to improve the efficiency of translational science," said Dr. Fred Ledley, founding director of the center and a co-author of the paper. "Modeling the process of translational science, it is clear that greater emphasis needs to be placed on expediting the growth of basic biomedical research to improve the efficiency, timelines, and cost of bringing new cures to market."
News Article | May 15, 2017
Mr. Freda joined the Hamilton Board of Directors in June, 2014 and chairs the Board's Audit Committee. Mr. Brown has been a member of the Board since Hamilton's establishment in December 2013 and is Chairman of the Finance and Governance Committee. "It is with regret that we have accepted Brian's resignation from Hamilton," said Mr. Freda. "He is an industry icon with a well-deserved reputation for visionary leadership. We have had the privilege of experiencing this first-hand at Hamilton. "However, we have in David an experienced industry CEO who has been with the Company since inception. He is an ideal resource to lead Hamilton through this transition. "With a superlative management team, and a Board of Directors representing a cross section of disciplines from the insurance, finance and technology industries, we are well-prepared to continue to execute our mission of writing the future of risk. "In addition, our relationship with Two Sigma, our technology and investment partner, has been an extremely productive one since Hamilton's launch at the end of 2013. Our experience with Attune, the technology-enabled company established with Two Sigma and AIG, has demonstrated the huge potential in applying data science and analytics to transform the underwriting process. "We are all excited about the potential for ongoing growth and development at Hamilton." Mr. Freda concluded his distinguished career at Deloitte LLP in 2014, having worked for the firm for 40 years following his graduation from Bentley University in Waltham, Massachusetts. At Deloitte, Mr. Freda served on a wide range of multinational engagements, interacting with clients' audit committees, boards of directors and senior management to address critical, strategic issues. Mr. Freda's many senior positions at Deloitte included Chairman of the Risk Committee and the Audit Committee of Deloitte Touche Tohmatsu Limited's Board of Directors, Managing Partner of Deloitte's U.S. client initiatives, and Regional Managing Partner of the Northeast, Deloitte's largest U.S. region. Mr. Freda has been involved in many industry associations and community organizations, including the Board of Trustees of Bentley University. He is a member of the Board of Directors of The Guardian Insurance Company of America and State Street Corporation. Mr. Brown served as the Chief Executive Officer of Flagstone Reinsurance Holdings Ltd. from its foundation in October 2005 until November 2012. He previously served as Chief Executive of Centre Solutions from 1994 until 1997. Before joining Centre Solutions, he was a Partner with Ernst & Young. He has been Chairman of the Board at the Bermuda Stock Exchange since 2000. Mr. Brown is a Fellow of the Institute of Chartered Accountants in England and Wales. He is also a member of the Institute of Chartered Accountants of Bermuda. Hamilton Insurance Group is the Bermuda-based holding company for property and casualty insurance and reinsurance operations in Bermuda, the U.S. and at Lloyd's. The company leverages analytics and research to create underwriting and investment value for its clients and shareholders. For more information, please visit www.hamiltongroup.com | Twitter: @HamiltonInsures | LinkedIn: https://www.linkedin.com/company/hamilton-insurance-group To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/hamilton-insurance-group-appoints-william-c-freda-as-chairman-and-david-a-brown-as-interim-group-ceo-300457280.html
News Article | May 25, 2017
CHATTANOOGA, Tenn.--(BUSINESS WIRE)--At the annual meeting of shareholders today, Unum (NYSE: UNM) CEO Richard P. (Rick) McKenney addressed the company’s strong performance, industry leadership, and the growing need for the financial protection Unum provides. “2016 was an excellent year for us, continuing a strong track record of success,” McKenney said. “We delivered on our promises to customers and shareholders, while continuing to build on the strong Unum brand. The result was one of the best years in our company’s history.” “Most importantly,” he added, “we are strategically well-positioned now and for the future as the need for our products and services is only increasing.” In 2016, Unum earned record revenues of nearly $11.1 billion and paid approximately $6.9 billion in benefits. Over the course of the year, Unum protected more than 35 million policyholders, helped 189,000 companies attract and retain employees, and assisted 327,000 people in returning to work following a disability. Unum also achieved historically high levels of customer and broker satisfaction, and made strategic investments to support disciplined growth. Additionally, McKenney noted that Unum’s total shareholder return has outperformed its peers across multiple indices for the last decade. “Unum has been a very good performer and an excellent long-term investment during one of the most challenging economic periods in memory,” he said. The company generated a 9.76% compound annual return to shareholders from 2006 through 2016. “Our mission now is to build on our company’s progress,” he added. “Although much of the uncertainty from last year continues, we entered 2017 with strong momentum and remain intensely focused on the disciplined execution of our business plan – and on serving the needs of working people and their families throughout the U.S. and U.K.” In discussing the company’s future, McKenney said the need for financial protection benefits continues to grow. “One in four U.S. workers between 20 and 50 years old will be out of work at some point in their career due to a disability,” he said. “We also know that 40% of families live paycheck-to-paycheck, and half would have trouble coming up with the money to cover a $2,000 emergency. Yet most striking of all, 70% of workers lack disability protection.” To fill the void, Unum has invested heavily in understanding the best potential coverage options for employees in different life stages. “Today, there are four distinct generations working side-by-side,” McKenney noted. “This trend affirms our true purpose of providing financial security and peace of mind for an increasingly diverse workforce. It also demands that we push beyond the one-size-fits-all model and be certain our offerings are valuable for workers in any stage of their careers.” McKenney attributed the company’s consistent success to competitive advantages in claims management, risk management and distribution, as well as its singular focus on employee benefits. “Creating new products, enhancing existing offerings, and finding new ways to create great customer experiences ensure that we remain at the forefront of the employee benefits market,” he said. “This helps to emphasize a key differentiator for Unum: Delivering benefits at the workplace is our sole business. That focus sets us apart from many of our competitors.” Also during today’s meeting, Thomas R. Watjen concluded his two-year term as chairman of the board of directors, following 12 years as the company’s CEO. “It’s been an unbelievable privilege to have served as your CEO for over a dozen years and as your chairman these past two years,” Watjen said. “I’ll miss being part of this special company and group of people, but I leave knowing that the company is on sound footing and in good hands.” McKenney thanked Watjen for his instrumental role in shaping the company and providing a solid foundation during his time as CEO and chairman of the board. He also noted that Unum’s position as an industry leader is stronger than ever, thanks in large part to Watjen’s vision and leadership. Kevin Kabat, who has served as the board’s Lead Independent Director over the past year, becomes the new chairman of Unum’s board of directors. “We all have great confidence in Kevin’s ability to lead the board in its oversight of the company,” McKenney said. “His experience on other public company boards, as well as his leadership positions on this board, make him an ideal candidate for this new role.” Also at today’s meeting, Unum shareholders voted to re-elect 11 directors for terms expiring in 2018: Theodore Bunting, group president of utility operations at Entergy Corporation; Michael Caulfield, former president of Mercer Human Resource Consulting; Joseph Echevarria, retired CEO of Deloitte LLP; Cynthia Egan, retired president of T. Rowe Price Retirement Plan Services; Pamela Godwin, President of Change Partners, Inc.; Kevin Kabat, chairman of the board of Unum Group and retired president and CEO of Fifth Third Bancorp; Timothy Keaney, former vice chairman of The Bank of New York Mellon Corporation; Gloria Larson, president of Bentley University; Rick McKenney, president and CEO of Unum Group; Ronald O’Hanley, president and CEO of State Street Global Advisors and vice chairman of State Street Corporation; and Francis Shammo, retired CFO of Verizon Communications. Edward Muhl, retired national leader of PricewaterhouseCoopers LLP, has reached mandatory retirement age and retired from the board today. Separately today, Unum’s board of directors authorized an increase of 15 percent in the quarterly dividend paid on the company’s common stock. The new rate of 23 cents per common share, or 92 cents per share on an annual basis, will be effective with the dividend expected to be paid in the third quarter of 2017. The board also authorized the repurchase of up to $750 million of the company’s outstanding common stock through Nov. 25, 2018, replacing the previous authorization of $750 million that was scheduled to expire later this year. Unum Group (www.unum.com) is a leading provider of financial protection benefits in the United States and the United Kingdom. Its primary businesses are Unum US, Colonial Life, Starmount and Unum UK. Unum’s portfolio includes disability, life, accident and critical illness, dental and vision coverage, which help protect millions of working people and their families in the event of an illness or injury. Unum also provides stop-loss coverage to help self-insured employers protect against unanticipated medical costs. The company reported revenues of $11 billion in 2016, and provided $6.9 billion in benefits. For more information, connect with us on Facebook, Twitter and LinkedIn. Certain information in this press release constitutes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are those not based on historical information, but rather relate to our outlook, future operations, strategies, financial results, or other developments and speak only as of the date made. These forward-looking statements, including statements about progress and momentum for 2017, are subject to numerous assumptions, risks, and uncertainties, many of which are beyond our control. The following factors, in addition to other factors mentioned from time to time, may cause actual results to differ materially from those contemplated by the forward-looking statements: (1) sustained periods of low interest rates; (2) fluctuation in insurance reserve liabilities and claim payments due to changes in claim incidence, recovery rates, mortality and morbidity rates, and policy benefit offsets due to, among other factors, the rate of unemployment and consumer confidence, the emergence of new diseases, epidemics, or pandemics, new trends and developments in medical treatments, the effectiveness of our claims operational processes, and changes in government programs; (3) unfavorable economic or business conditions, both domestic and foreign; (4) legislative, regulatory, or tax changes, both domestic and foreign, including the effect of potential legislation and increased regulation in the current political environment; (5) investment results, including, but not limited to, changes in interest rates, defaults, changes in credit spreads, impairments, and the lack of appropriate investments in the market which can be acquired to match our liabilities; (6) a cyber attack or other security breach could result in the unauthorized acquisition of confidential data; (7) the failure of our business recovery and incident management processes to resume our business operations in the event of a natural catastrophe, cyber attack, or other event; (8) increased competition from other insurers and financial services companies due to industry consolidation, new entrants to our markets, or other factors; (9) execution risk related to our technology needs; (10) changes in our financial strength and credit ratings; (11) damage to our reputation due to, among other factors, regulatory investigations, legal proceedings, external events, and/or inadequate or failed internal controls and procedures; (12) actual experience that deviates from our assumptions used in pricing, underwriting, and reserving; (13) actual persistency and/or sales growth that is higher or lower than projected; (14) changes in demand for our products due to, among other factors, changes in societal attitudes, the rate of unemployment, consumer confidence, and/or legislative and regulatory changes, including healthcare reform; (15) effectiveness of our risk management program; (16) contingencies and the level and results of litigation; (17) availability of reinsurance in the market and the ability of our reinsurers to meet their obligations to us; (18) ineffectiveness of our derivatives hedging programs due to changes in the economic environment, counterparty risk, ratings downgrades, capital market volatility, changes in interest rates, and/or regulation; (19) changes in accounting standards, practices, or policies; (20) fluctuation in foreign currency exchange rates; (21) ability to generate sufficient internal liquidity and/or obtain external financing; (22) recoverability and/or realization of the carrying value of our intangible assets, long-lived assets, and deferred tax assets; and (23) terrorism, both within the U.S. and abroad, ongoing military actions, and heightened security measures in response to these types of threats. For further discussion of risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements, see Part 1, Item 1A “Risk Factors” of our annual report on Form 10-K for the year ended December 31, 2016, and, to the extent applicable, our subsequent quarterly reports on Form 10-Q. The forward-looking statements in this press release are being made as of the date of this press release, and the company expressly disclaims any obligation to update or revise any forward-looking statement contained herein, even if made available on our website or otherwise.
News Article | May 24, 2017
BOSTON, MA--(Marketwired - May 24, 2017) - TrueMotion, the leader in providing mobile Usage Based Insurance (UBI) services, today announced Ted Gramer as Chief Executive Officer. With more than 20 years in the insurance and finance industries, Gramer's experience and knowledge will accelerate TrueMotion's aggressive growth in the global insurance space. Gramer spent more than a decade with Liberty Mutual Insurance in a variety of executive leadership positions, including Executive Vice President & Chief Claims Officer and Executive Vice President of Liberty International. Most recently, Gramer was the Managing Director for Global Property at Solera, a global leader in data and software for automotive, home ownership and digital identity management. Gramer holds a Bachelor of Science in Management from Bentley University, an MBA from the MIT Sloan School of Management and is a Chartered Financial Analyst (CFA). "Ted's experience in insurance, analytics and early stage companies is a perfect fit for TrueMotion," said Scott Griffith, chairman and co-founder of TrueMotion. "He's a former insurance executive who understands the practical challenges carriers face attracting new customers, managing emerging loss trends and struggling to simplify the claims process. He also has years of experience applying big data and innovation across different industries in the U.S. and internationally. We couldn't be happier to have him on board." TrueMotion's mobile apps use the sensors built into smartphones (iOS and Android) plus data science to objectively capture driver behavior (hard braking, acceleration, distraction, etc.) and give the driver a score at the end of each trip. The company uses machine learning and signal processing techniques to filter out non-car trips (train, bus, bike, etc.), and its patented approach identifies whether someone is actually behind the wheel or in the passenger seat. In addition to the mobile apps, TrueMotion offers a big data platform that provides comprehensive driving activity, individual scores and analytics to inform customer insights. "After decades of declining accident frequency, consumers and insurance carriers are beginning to see the financial and human toll of distracted driving," said Gramer. "TrueMotion uses the same mobile phones that cause the problem to change behavior and make our roads safer. I'm excited to be part of such a talented and passionate team tackling this problem." In the first quarter of this year, 27,000 drivers who use TrueMotion technology logged 68 million miles and reduced their distracted driving by 20 percent per trip. This is a significant reduction in unsafe driving that is now a leading cause of injuries, deaths and costly auto repairs. About TrueMotion Headquartered in Boston, Mass., TrueMotion combines the power of mobile technology, machine learning and data science to reduce the number of automobile crashes and fatalities. Its patented technology uses the sensors built into smartphones to accurately identify drivers and score their overall driving habits, including distracted driving. Up to 75 percent of drivers who use TrueMotion technology reduce distracted driving and other risky behaviors. The company provides an enterprise version of its technology to leading insurers, as well as free consumer apps under the TrueMotion brand. More information is available at goTrueMotion.com.
News Article | April 17, 2017
Wilmington Trust, N.A. hired Joshua Stowell as senior trust sales representative for its Global Loan Agency Services group in the Global Capital Markets division. Based in the company’s Boston office, he will focus on expanding loan agency services to alternative capital providers, business development corporations, and direct lenders. Stowell will also sell successor loan agency services. Stowell has more than a decade of experience in finance. He joins Wilmington Trust from U.S. Bank, where he was a business development officer responsible for selling domestic corporate trust products and services including loan agency, custody, CLO trustee, and middle-office services. Prior to that, he was a manager of collateralized debt obligation (CDO) analytics at U.S. Bank, overseeing a group of analysts and creating complex CDO models for structured deals. “The addition of Josh to our Global Loan Agency Services business builds on our status as a trusted provider of independent loan agency services in the U.S. and Europe,” said Pat Trainor, senior vice president and sales manager of Global Capital Markets. “Josh developed a strong reputation in the syndicated and middle market loan space by leveraging his valuable experience in both transaction administration and business development. “Josh will work in close collaboration with Chris Monigle, our veteran client development officer. Together, they will be a powerful business development team in this space.” Stowell earned a Bachelor of Science in Finance from Bentley University, and also studied at the Vienna University of Economics and Business. He is based in Wilmington Trust’s Boston office, located at 280 Congress St., and can be reached at (617) 457-2067. ABOUT WILMINGTON TRUST Wilmington Trust, N.A. provides Corporate and Institution services including institutional trustee, agency, asset management, retirement plan services, and administrative services for clients worldwide who use capital markets financing structures. The corporate and institutional division is distinguished from many competitors by its status as a core business of Wilmington Trust, as well as the experience and expertise of its global staff and its multi-jurisdictional presence. Wilmington Trust also provides Wealth Advisory services with a wide array of personal trust, financial planning, fiduciary, asset management, and family office solutions designed to help high-net-worth individuals and families grow, preserve, and transfer wealth. Wilmington Trust has clients in all 50 states and in more than 90 countries, with offices throughout the United States and internationally in London, Dublin, and Frankfurt. For more information, visit http://www.WilmingtonTrust.com. Wilmington Trust is a registered service mark. Wilmington Trust Corporation is a wholly owned subsidiary of M&T Bank Corporation. Wilmington Trust Company, operating in Delaware only, Wilmington Trust, N.A., M&T Bank and certain other affiliates, provide various fiduciary and non-fiduciary services, including trustee, custodial, agency, investment management and other services. International corporate and institutional services are offered through Wilmington Trust Corporation's international affiliates. Loans, credit cards, retail and business deposits, and other business and personal banking services and products are offered by M&T Bank, member FDIC.
News Article | April 10, 2017
MADISON, Wis., April 10, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today announces it has appointed Douglas J. Swirsky and Frederick W. Driscoll to its board of directors. “Both Fred and Doug bring extensive operational and industry experience that should prove invaluable to Cellectar as we enter this next phase of the company’s development,” said Jim Caruso, president and CEO of Cellectar Biosciences. “We look forward to working with both and benefitting from their contributions.” Douglas J. Swirsky has served as president and chief executive officer of GenVec, Inc. since 2013, and also serves as a member of GenVec's board of directors. Mr. Swirsky also currently serves as chairman of the board of Fibrocell Science, Inc. From 2006 through 2014, he served as senior vice president, chief financial officer, treasurer and corporate secretary of GenVec. Prior to joining GenVec in September 2006, Mr. Swirsky worked at Stifel Nicolaus where he served as a managing director and the head of Life Sciences Investment Banking. Previously, Mr. Swirsky held investment banking positions at UBS, PaineWebber, Morgan Stanley, and Legg Mason. His experience also includes positions in public accounting and consulting. He received his undergraduate degree in business administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University. Mr. Swirsky is a certified public accountant and a CFA® charterholder. Frederick W. Driscoll served as chief financial officer at Flexion Therapeutics (Flexion) from 2013 to 2017, spearheading a successful IPO in 2014. Prior to joining Flexion, he was chief financial officer at Novavax, Inc., a publicly traded biopharmaceutical company, from 2009 to 2013. Previously, Mr. Driscoll also served as chief financial officer from 2007 to 2008, and subsequently chief executive officer from 2008 to 2009, at Genelabs Technologies, Inc., a publicly traded biopharmaceutical and diagnostics company that was acquired by GlaxoSmithKline; and chief executive officer at OXiGENE, Inc., a biopharmaceutical company, from 2000 to 2006. He has also served as chairman of the board and audit committee chair at OXiGENE and as a member of the audit committee for Cynapsus, which was sold to Sunovion Pharmaceuticals in 2016. Mr. Driscoll earned a bachelor’s degree in accounting and finance from Bentley University. About Cellectar Biosciences, Inc. Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer-targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's PDC platform is based on the company's proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. Cellectar's PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 is currently being evaluated under an orphan drug designated Phase I clinical study in patients with relapsed or refractory multiple myeloma, as well as a Phase II clinical study to assess efficacy in a range of B-cell malignancies. The company is also developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1603-PTX), a preclinical-stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts. For more information please visit www.cellectar.com. This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2016. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.
News Article | April 26, 2017
CHICAGO, April 26, 2017 (GLOBE NEWSWIRE) -- North American Company for Life and Health Insurance® is proud to announce the appointment of Steve Zimmerman as Sales Vice President. He will support independent life insurance agencies in his territory on implementing North American’s proven Partner Program, which helps Partner Agencies grow their business, in addition to consulting sales and marketing strategies, recruiting, and case placement. “Steve joins us with great experience and a track record of success managing long-term relationships with brokerage distributors and driving overall sales and profitability,” said Garth A. Garlock, Senior Vice President & Chief Distribution Officer. “In addition to his professional achievements, his passion for our business and alignment with our culture make him a terrific fit for the role.” Zimmerman will be responsible for assisting insurance agencies primarily in the Northeast quadrant of the United States, including the following key states: Maryland, Pennsylvania, Delaware, New Jersey, Connecticut, Massachusetts, New Hampshire, Vermont and Maine. Prior to joining North American Company, Zimmerman was Regional Sales Director for Transamerica. Zimmerman has earned designations for Certified Financial Planner (CFP), Chartered Life Underwriter (CLU), Chartered Financial Consultant (ChFC) and Accredited Estate Planner (AEP). He holds a Bachelor of Science in marketing and management from Bentley University. ABOUT NORTH AMERICAN COMPANY North American Company for Life and Health Insurance is a member of Sammons® Financial Group, Inc. Since 1886, North American has established a tradition of providing quality insurance products to consumers throughout the U.S. We offer a comprehensive portfolio of term, universal life, and indexed universal life insurance products. North American also offers a wide variety of traditional fixed and fixed index annuities and consistently ranks among the top fixed index annuity carriers in the U.S.1 In 2016, we ranked number 10 in life insurance sales, as part of Sammons Financial Group.2 For more information, please visit www.northamericancompany.com. Sammons® Financial Group is comprised of North American Company for Life and Health Insurance®, Midland National® Life Insurance Company, including its divisions, Sammons Annuity GroupSM and Sammons® Corporate Markets Group, Sammons Retirement Solutions® Inc. and Sammons Financial Network® LLC, member FINRA. 1 Source: AnnuitySpecs, Quarterly Indexed Sales & Market Report 2 Source: LIMRA International, U.S. Retail Individual Life Insurance Sales, fourth quarter 2016 results. Sales based on annualized premium plus excess.
News Article | April 27, 2017
BEDFORD, MA--(Marketwired - Apr 27, 2017) - Mass Innovation Nights (MIN) and The MITRE Corporation are collaborating to host #MIN98, an IoT-focused startup showcase and networking event, on Wednesday, May 10th from 6:00 p.m. to 8:30 p.m. The event will be held at MITRE's Massachusetts headquarters, 202 Burlington Road, Bedford, MA. "Mass Innovation Nights 98 will be our third event with MITRE, and we appreciate their commitment to supporting the local innovation community," said Bobbie Carlton, the founder of Innovation Nights, and Innovation Women. "MITRE continues to demonstrate this commitment to innovation in the Boston region." "We continue to see value in supporting local entrepreneurship events," said Pete Sherlock, MITRE senior vice president and chief operating officer. "Engaging with the innovation community is essential to our public interest mission. We're addressing complex challenges of national and global significance and access to local startups is a key part of that. Our role for our government sponsors is to be a bridge for innovation." Mass Innovation Nights #98 features experts, networking, tabletop presentations with new local products and presentations from the winners of online voting. The event is open to the public and free to attend. Two student-founded startups from Bentley University, Sales Sparks and Sooshay, will also present. Guests are encouraged to use hashtag #MIN98 and @MassInno to share their photos and commentary. Companies showcasing new products at #MIN98 include: There will also be experts from: Mass Innovation Nights gatherings typically generate hundreds of Tweets, Facebook posts, blogs, and videos, and are key visibility drivers for the launching companies. To attend, please RSVP by May 2, 2017. About Mass Innovation Nights Mass Innovation Nights (MIN) offers an opportunity for people interested in innovative new products to connect live and online. Each month, different companies launch new products with Innovation Nights and the social media community helps spread the word. The popular product launch party and networking event draws attendees from the entire region. Over the past 8 years, it has launched almost 1000 new products which have collectively received more than $1.3 billion in funding. Follow MIN on Twitter or visit the website at mass.innovationnights.com/. About MITRE MITRE is a not-for-profit organization that operates research and development centers sponsored by the federal government. Learn more.
Chau M.,University of Hong Kong |
Xu J.,Bentley University
MIS Quarterly: Management Information Systems | Year: 2012
The increasing popularity of Web 2.0 has led to exponential growth of user-generated content in both volume and significance. One important type of user-generated content is the blog. Blogs encompass useful information (e.g., insightful product reviews and information-rich consumer communities) that could potentially be a gold mine for business intelligence, bringing great opportunities for both academic research and business applications. However, performing business intelligence on blogs is quite challenging because of the vast amount of information and the lack of commonly adopted methodology for effectively collecting and analyzing such information. In this paper, we propose a framework for gathering business intelligence from blogs by automatically collecting and analyzing blog contents and bloggers' interaction networks. Through a system developed using the framework, we conducted two case studies with one case focusing on a consumer product and the other on a company. Our case studies demonstrate how to use the framework and appropriate techniques to effectively collect, extract, and analyze blogs related to the topics of interest, reveal novel patterns in the blogger interactions and communities, and answer important business intelligence questions in the domains. The framework is sufficiently generic and can be applied to any topics of interest, organizations, and products. Future academic research and business applications related to the topics examined in the two cases can also be built using the findings of this study.
Stavrulaki E.,Bentley University
International Journal of Production Economics | Year: 2011
We study a retailer's inventory policy for two products. The products are substitutable and have inventory dependent demand, so a higher inventory level of a product increases its sales. We model the joint effect of demand stimulation and product substitution on inventory decisions by considering a single-period, stochastic demand setting. We provide the first order optimality conditions for the profit maximizing order quantities and interpret them using marginal analysis. We also consider two heuristic solutions that separately account for either demand stimulation or product substitution. Our numerical analysis reveals that the optimal policy by appropriately using sales information that quantifies substitution and demand stimulation can produce significantly higher profits. The profit benefits are lessened under certain circumstances, such as when the two products have similar critical fractile values, suggesting that in such instances the heuristics may be used effectively. © 2010 Elsevier B.V. All rights reserved.